Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnerships
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnerships
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > Epidemiological study sheds light on complex link between ovarian cancer and ovulation
  • News

Epidemiological study sheds light on complex link between ovarian cancer and ovulation

  • 9 February 2023
  • Janet Fricker
Epidemiological study sheds light on complex link between ovarian cancer and ovulation
Total
0
Shares
0
0
0
0
0

Women who ovulate for longer over the course of their lifetimes may have a higher risk of developing ovarian cancer. The international epidemiological study, published in Journal of the National Cancer Institute, 23 January, found that each additional year of ovulation was associated with a 4% increase in the risk of epithelial ovarian cancer. However, the picture was not that clear cut, with two ovarian cancer subtypes (mucinous tumours and high-grade serous) showing distinctly different risk factor profiles.

“Our findings show that all ovarian cancers are not equal. We think of epithelial ovarian cancer as one disease, but it’s actually a group of different diseases. The results show that different subtypes have different origins and point to where basic science research needs to go next to better understand how to prevent these diseases,” Francesmary Modugno, the senior author, tells Cancerworld.

Oral contraceptives, having children, and breastfeeding have all shown consistent protective effects for ovarian cancer. However, while studies demonstrate that lifetime ovulatory years are associated with increased epithelial ovarian cancer risk, it has been unclear whether protective mechanisms arise through ovulation suppression alone or other factors. Furthermore, no individual study has been large enough to analyse individual epithelial ovarian cancer subtypes. Epithelial ovarian cancers account for over 95% of ovarian malignancies and are thought to arise from trauma and wound repair of the surface layer of ovarian cells as a result of ovulation. The main subtypes include high-grade serous ovarian carcinoma, endometrioid carcinoma, low-grade serous ovarian carcinoma, mucinous carcinoma, and ovarian clear cell carcinoma.

For the current study, the investigators pooled primary data from 21,267 women with ovarian cancer and 26,204 healthy controls who had been involved in 25 case-controlled studies. The studies, performed across four continents and nine countries, were undertaken by members of the Ovarian Cancer Association Consortium (OCAC), a forum of ovarian cancer investigators formed in April 2005. “By combining data from individual studies, we had enough power for the first time to carefully look at the individual subtypes. We wanted to get a handle on whether there were different risk factors that would imply that different subtypes arose from different origins,” explains Modugno, from the Magee-Womens Research Institute and UPMC Hillman Cancer Center at the University of Pittsburgh.

For ovarian cancer cases and controls (without ovarian cancer), investigators calculated lifetime ovulatory years as the time between the woman’s first and last menstrual period (her menstrual span), subtracting any time when she would not have been ovulating (pregnancy, oral contraceptives, breastfeeding). Multivariable logistic regression was used to estimate the odds ratio for the association between lifetime ovulatory years and epithelial ovarian cancer. The team utilised 12 different algorithms to assess the robustness of their results.

Overall, results showed that for all epithelial ovarian cancer subtypes, each additional year of ovulation was associated with a 4% increased risk of ovarian cancer.

When all subtypes were considered together, the estimated model coefficient protective effect for oral contraceptive use was 4.45 times greater than expected for the time period not ovulating; for pregnancy, the effect was 12 to 15 times greater, and for breastfeeding, it was 13 times greater. “The magnitude of these associations varied substantially from expectations according to the time period women were not ovulating. These data tell us that ovulation suppression alone is not the only mechanism underlying the protective effects of these factors. If that were the case, you’d expect similar results for similar time periods of oral contraceptive use and pregnancy (both preventing ovulation) to deliver the same benefits,” explains Modugno.

For the mucinous epithelial ovarian cancer subtype, total ovulation over a woman’s lifetime was not associated with cancer. However, the different factors contributing to total ovulations (oral contraceptive use, pregnancy, and breastfeeding) were. “This underscores that the mechanism of action for mucinous ovarian cancer was not through suppressing ovulation but by some other means,” explains Modugno.

High-grade serous ovarian cancer stood out as the only subtype where the mechanism of action appeared to be through ovulation suppression alone. “This is surprising because high-grade serous ovarian cancers are believed to arise in the fallopian tubes rather than the ovary. Thus, there must be something about ovulation beyond ovarian trauma impacting risk,” says Modugno. “Emerging data suggest that it may be the follicular fluid released at ovulation which reaches the fallopian tube that may lead to cancer initiation.”

The authors conclude that, taken together, the data imply that mechanisms beyond ovulation suppression, such as hormonal alterations or inflammation, are contributing to the association between lifetime ovulatory years and epithelial ovarian cancer. Going forward, Modugno says, the team hope to use the information to develop risk assessment models that clinicians can use to screen women to identify those at high risk who may benefit from specific prevention strategies.

The team also hope their epidemiological work will inspire basic scientists to undertake animal and in-vitro ovarian cancer studies to shed light on potential mechanisms. “Understanding these mechanisms can ultimately open new avenues for ovarian cancer prevention,” says Modugno.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • breastfeeding
  • case-control study
  • epithelial ovarian cancer
  • high grade serous ovarian cancer
  • lifetime ovulation years
  • mucinous epithelial ovarian cancer
  • oral contraceptives
  • ovulation
  • pooled analysis
  • pregnancy
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • News

Cancer could overtake cardiovascular disease as leading cause of death in type 2 diabetes

  • 9 February 2023
  • Janet Fricker
View Post
Next Article
  • Voices

Childhood cancer: let’s close this equity gap of haves and have nots

  • 10 February 2023
  • Daniel McKenzie
View Post
You May Also Like
View Post
  • News

Improving outcomes in elderly patients taking multiple medications

  • Janet Fricker
  • 24 March 2023
View Post
  • News

Localised prostate cancer: active monitoring offers valid option

  • Janet Fricker
  • 24 March 2023
View Post
  • News

Radiotherapy can be safely omitted in older women with low-risk breast cancer

  • Janet Fricker
  • 10 March 2023
View Post
  • News

Plant-based diets cut risk of prostate cancer progression and recurrence by over 50%

  • Janet Fricker
  • 9 March 2023
A blood test to recognize prostate cancer
View Post
  • News

New prostate cancer blood test combining PSA with epigenetic test could reduce biopsies

  • Janet Fricker
  • 23 February 2023
View Post
  • News

Telomere shortening mediates tumour suppression

  • Janet Fricker
  • 23 February 2023
View Post
  • News

Cancer could overtake cardiovascular disease as leading cause of death in type 2 diabetes

  • Janet Fricker
  • 9 February 2023
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Improving outcomes in elderly patients taking multiple medications
    • 24 March 2023
  • Localised prostate cancer: active monitoring offers valid option
    • 24 March 2023
  • Radiotherapy can be safely omitted in older women with low-risk breast cancer
    • 10 March 2023
  • Plant-based diets cut risk of prostate cancer progression and recurrence by over 50%
    • 9 March 2023
  • A blood test to recognize prostate cancer
    New prostate cancer blood test combining PSA with epigenetic test could reduce biopsies
    • 23 February 2023
Article
  • ‘Fragile’ cancer patients hit by Turkish earthquake need urgent support
    • 22 March 2023
  • Expert cancer surgery: could VR help speed up and standardise training?
    • 22 March 2023
  • Immunotherapy: three studies point to potential strategies to improve response
    • 10 March 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • AI in Surgery
    • 8 March 2023
  • COVID and haematological malignancies
    • 28 February 2023
  • Telemedicine Rehabilitation in the Cancer Care Continuum
    • 24 February 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnerships
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.